Free Trial

Acrivon Therapeutics (ACRV) Institutional Ownership

Acrivon Therapeutics logo
$1.15 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 +0.02 (+1.30%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Institutional Ownership Changes (13F Filings) for Acrivon Therapeutics (NASDAQ:ACRV)

Current
Institutional Ownership
Percentage
71.62%
Number of
Institutional Buyers
(last 12 months)
21
Total
Institutional Inflows
(last 12 months)
$23.26M
Number of
Institutional Sellers
(last 12 months)
13
Total
Institutional Outflows
(last 12 months)
$2.75M
Get ACRV Insider Trade Alerts

Want to know when executives and insiders are buying or selling Acrivon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

ACRV Institutional Buying and Selling by Quarter

Acrivon Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/16/2025 Goldman Sachs Group Inc.57,519$117K0.0%-75.8%0.183%
5/15/2025 Baker BROS. Advisors LP22,809$46K0.0%-56.9%0.073%
5/13/2025 Wealthedge Investment Advisors LLC56,467$115K0.1%+420.1%0.180%
5/12/2025 Nuveen LLC13,402$27K0.0%N/A0.043%
5/12/2025 Invesco Ltd.35,315$72K0.0%N/A0.113%
3/12/2025 Wealthedge Investment Advisors LLC10,857$65K0.0%N/A0.035%
2/17/2025Nuveen Asset Management LLC13,402$81K0.0%-48.0%0.043%
2/17/2025 OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC102,784$619K0.0%+29.7%0.330%
2/17/2025 Corton Capital Inc.12,159$73K0.0%N/A0.039%
2/17/2025 Bridgeway Capital Management LLC74,600$449K0.0%-3.1%0.240%
2/17/2025 Citadel Advisors LLC2,119,646$12.76M0.0%-1.0%6.807%
2/17/2025 Acorn Capital Advisors LLC405,237$2.44M1.3%N/A1.301%
2/14/2025 Northern Trust Corp117,323$706K0.0%+11.3%0.377%
2/14/2025 Dimensional Fund Advisors LP37,063$223K0.0%+20.2%0.119%
2/13/2025 Marshall Wace LLP597,794$3.60M0.0%-26.2%1.920%
2/13/2025 Barclays PLC38,091$228K0.0%+14.4%0.122%
2/13/2025 Renaissance Technologies LLC49,400$297K0.0%+7.6%0.159%
2/12/2025 Trexquant Investment LP16,871$102K0.0%-44.5%0.054%
2/12/2025 JPMorgan Chase & Co.25,809$155K0.0%-24.1%0.083%
2/11/2025 American Century Companies Inc.17,588$106K0.0%+14.2%0.056%
2/6/2025 Charles Schwab Investment Management Inc.113,840$685K0.0%-2.1%0.366%
2/4/2025 Bank of New York Mellon Corp27,635$166K0.0%-6.4%0.089%
1/24/2025 China Universal Asset Management Co. Ltd.6,602$40K0.0%N/A0.021%
12/26/2024 JPMorgan Chase & Co.33,991$238K0.0%+548.3%0.109%
12/13/2024 Exome Asset Management LLC116,757$817K0.5%N/A0.375%
11/19/2024 Barclays PLC33,306$233K0.0%+51.2%0.107%
11/16/2024 Geode Capital Management LLC302,103$2.12M0.0%-2.0%0.975%
11/15/2024 Barclays PLC33,306$233K0.0%+51.2%0.108%
11/15/2024 State Street Corp225,896$1.58M0.0%+26.4%0.729%
11/12/2024 Charles Schwab Investment Management Inc.116,253$814K0.0%-19.2%0.375%
10/10/2024 Exchange Traded Concepts LLC20,348$142K0.0%-52.5%0.066%
8/16/2024 Perceptive Advisors LLC5,360,858$31.09M0.7%+78.2%17.362%
8/14/2024 Marshall Wace LLP948,866$5.50M0.0%+58.8%3.073%
8/13/2024 Sands Capital Ventures LLC2,122,605$12.31M4.1%+28.4%6.874%
8/12/2024 XTX Topco Ltd10,493$61K0.0%N/A0.034%
8/9/2024 Renaissance Technologies LLC54,500$316K0.0%-46.9%0.177%
8/9/2024 Dimensional Fund Advisors LP10,066$58K0.0%N/A0.033%
8/1/2024 Rhumbline Advisers16,209$94K0.0%+48.9%0.052%
7/26/2024 Bank of New York Mellon Corp36,632$212K0.0%+50.1%0.119%
5/15/2024 Baker BROS. Advisors LP52,885$378K0.0%N/A0.234%
Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad)

Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?

Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave.
5/14/2024 American International Group Inc.6,016$43K0.0%+39.2%0.027%
5/10/2024 Vanguard Group Inc.507,185$3.63M0.0%+6.6%2.241%
1/5/2024 Exchange Traded Concepts LLC13,289$65K0.0%+34.0%0.060%
11/13/2023 Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020%
9/21/2023 Barclays PLC14,263$184K0.0%-16.0%0.065%
8/10/2023 AAF Wealth Management LLC10,678$138K0.1%N/A0.049%
7/20/2023 Exchange Traded Concepts LLC11,709$152K0.0%N/A0.053%
5/8/2023 Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798%
2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360%
2/14/2023 RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028%
2/13/2023 Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913%
2/10/2023 NEA Management Company LLC481,677$4.44M0.2%N/A2.306%
2/1/2023 Bank of Montreal Can42,444$545K0.0%N/A0.203%
(Data available from 1/1/2016 forward)

ACRV Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of ACRV shares?

During the previous two years, 34 institutional investors and hedge funds held shares of Acrivon Therapeutics. The most heavily invested institutionals were Perceptive Advisors LLC ($31.09M), Citadel Advisors LLC ($12.76M), Sands Capital Ventures LLC ($12.31M), Vanguard Group Inc. ($3.63M), Marshall Wace LLP ($3.60M), Acorn Capital Advisors LLC ($2.44M), and Federated Hermes Inc. ($2.16M).Learn more on ACRV's institutional investors.

What percentage of Acrivon Therapeutics stock is owned by institutional investors?

71.62% of Acrivon Therapeutics stock is owned by institutional investors. Learn more on ACRV's institutional investor holdings.

Which institutional investors have been buying Acrivon Therapeutics stock?

Of the 26 institutional investors that purchased Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Perceptive Advisors LLC ($2.35M), Sands Capital Ventures LLC ($470K), Acorn Capital Advisors LLC ($405.24K), Marshall Wace LLP ($351.40K), Exome Asset Management LLC ($116.76K), Wealthedge Investment Advisors LLC ($56.47K), and Baker BROS. Advisors LP ($52.89K).

How much institutional buying is happening at Acrivon Therapeutics?

Institutional investors have bought a total of 4,120,676 shares in the last 24 months. This purchase volume represents approximately $24.18M in transactions.

Which Acrivon Therapeutics major shareholders have been selling company stock?

Of the 15 institutional investors that sold Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Marshall Wace LLP ($212.07K), Goldman Sachs Group Inc. ($180.03K), Federated Hermes Inc. ($78.04K), Renaissance Technologies LLC ($48.10K), Charles Schwab Investment Management Inc. ($30.12K), Baker BROS. Advisors LP ($30.08K), and Exchange Traded Concepts LLC ($22.52K).

How much institutional selling is happening at Acrivon Therapeutics?

Institutional investors have sold a total of 669,262 shares in the last 24 months. This volume of shares sold represents approximately $3.53M in transactions.



This page (NASDAQ:ACRV) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners